Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels
Key claim: A French double-blind placebo-controlled trial (PostWelLB) is testing whether 3 months of daily Humiome® Post LB postbiotic (340 mg) reduces self-reported stress (PSS-10) in adults aged 50–75 with moderate stress.
Abstract
The placebo-controlled, double blind parallel intervention trial “PostWelLB” aims to test whether 3 months of daily supplementation with the postbiotic product “Humiome® Post LB” (HPLB; 340 mg / day) can reduce self-reported stress (PSS10 questionnaire)- in an older (50 - 75 years; all genders) population in France.
Why this matters
A French double-blind placebo-controlled trial (PostWelLB) is testing whether 3 months of daily Humiome® Post LB postbiotic (340 mg) reduces self-reported stress (PSS-10) in adults aged 50–75 with moderate stress.